1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


Table 1: 
Comparison of baseline characteristics, time of treatment stage, and clinical and radiologic outcomes between CSCP and RSP
CharacteristicPatientsP Value
CSCP (n = 75)RSP (n = 96)
Age (median) (IQR) (yr)74 (65–80)75 (63–81).932a
Male (No.) (%)36 (48.0)50 (48.3).596b
Diabetes mellitus (No.) (%)18 (24.0)22 (22.9).868b
Hypertension (No.) (%)39 (52.0)54 (56.3).580b
Dyslipidemia (No.) (%)8 (10.7)15 (15.6).346b
Atrial fibrillation (No.) (%)24 (32.0)24 (25.0).312b
CAOD (No.) (%)11 (10.5)13 (13.5).834b
Occlusion location (right) (No.) (%)35 (46.7)49 (51.0).570b
Initial NIHSS score (median) (IQR)14 (8–18)12 (8–15).049a
Time of treatment stage
    Symptom onset to hospital arrival (median) (IQR) (min)171 (55–544)92 (42–258).082a
    Door to puncture (median) (IQR) (min)87 (63–107)142 (106–177)<.001a
    Symptom onset to puncture (median) (IQR) (min)268 (145–665)254 (184–490).466a
    Procedure time (median) (IQR) (min)65 (49–86)59 (40–85).200a
Radiologic and clinical outcome (No.) (%)
    Successful recanalization (TICI 2b, 3)64 (85.3)79 (82.3).594b
    Good clinical outcome (3-m mRS 0–2)44 (58.7)59 (61.5).711b
    Excellent clinical outcome (3-m mRS 0–1)32 (42.7)35 (36.5).409b
  • Note:—CAOD indicates coronary artery occlusive disease; 3-m mRS, 3-month mRS.
  • ↵a P value obtained using the Mann-Whitney U test.
  • ↵b P value obtained using the Pearson χ2 test.